A COMMITTED PLAYER IN CARDIOVASCULAR CARE
A world where cardiovascular disease is no longer the leading cause of death – For patients. For healthcare providers. For society. That's the Amarin commitment.
Globally, more than four out of five cardiovascular disease (CVD) deaths are caused by heart attacks and strokes. At least 38% of premature deaths from noncommunicable diseases in people younger than 70 years of age are due to cardiovascular disease.1,2 19.8 million people died from CVDs in 2022, representing approximately 32% of all global deaths. Of these deaths, 85% were due to heart attack and stroke.2 There is an urgent need for action to address this healthcare crisis.
Amarin is focused on reducing the CVD burden for patients and communities and to advancing the science of cardiovascular care around the world. In addition to the ground-breaking science and clinical development, we own and support a global branded product approved by multiple regulatory authorities based on a track record of proven efficacy and safety and backed by robust clinical trial evidence. Our commercialization model includes a direct sales approach in the U.S. and an indirect distribution strategy internationally, through a syndicate of reputable and well-established partners with significant geographic expertise, covering close to 100 markets worldwide. Our success is driven by a dedicated, talented, and highly skilled team of experts passionate about the fight against the world's leading cause of death, CVD. Amarin is highly motivated to improve, innovate, and create shared value for our patients, employees, partners, and investors.
EVOLVING OUR NEXT CHAPTER FROM A TRACK RECORD OF SUCCESS
Amarin is built on a history of decisive actions. Read below for highlights of our history as a company committed to CVD prevention.
2008
Amarin Opens Research and Development Center
2009
Amarin Receives SPA For Phase 3 MARINE Study
2011
Amarin Commences 1st Patient In REDUCE-IT™ Trial
2012
Amarin Receives FDA Approval For VASCEPA® (Icosapent Ethyl)
2013
Amarin launches commercially in the U.S.
2015
Amarin Announces Partnership With Eddingpharm
2016
Amarin Wins Right To Promote Under First Amendment In The U.S.
2017
Amarin Announces Partnership In Canada
2018
Amarin Announces Results From REDUCE-IT™
2019
VASCEPA® Approved For Expanded Indication
2020
VASCEPA® Expansion Launches in the U.S.
2021
VAZKEPA® Approved By EMA And MHRA
2022
Amarin secures pricing and reimbursement for VAZKEPA® in the UK, Sweden, and Finland. TGA approval of VAZKEPA® is received in Australia
2023
VAZKEPA® is approved in New Zealand, Israel, and China.
2024
Amarin's IP protection for VAZKEPA® in Europe extends into 2039.
2025
Amarin Announces Partnership In Europe
RESOLUTE IN OUR VISION TO STOP CARDIOVASCULAR DISEASE FROM BEING THE LEADING CAUSE OF DEATH
At Amarin, we're focused on stopping cardiovascular disease (CVD) from being a leading cause of death. We believe that CVD patients, their loved ones, and society as a whole deserve a cardiovascular health management option that is reliable and effective in reducing the risk of CVD. There are people throughout the world, now and in the future, relying on us. We can give millions of patients the opportunity to change their lives for the better.
